Equities

Hangzhou Tigermed Consulting Co Ltd

Hangzhou Tigermed Consulting Co Ltd

Actions
  • Price (HKD)34.95
  • Today's Change3.90 / 12.56%
  • Shares traded5.40m
  • 1 Year change-22.93%
  • Beta--
Data delayed at least 15 minutes, as of Sep 27 2024 08:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The Company operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The Company conducts its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)8.17bn
  • Net income in HKD2.24bn
  • Incorporated2004
  • Employees9.70k
  • Location
    Hangzhou Tigermed Consulting Co Ltd15F618 Jiangnan Avenue, Binjiang DistrictHANGZHOU 310051ChinaCHN
  • Phone+86 57 189986795
  • Fax+86 57 189986795
  • Websitehttps://www.tigermedgrp.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.